Shijiazhuang Pharmaceutical Group (01093.HK): The new drug application for KN026 (AniTuo monoclonal antibody) and HB1801 (injection for docetaxel, albumin-bound) for neoadjuvant therapy has been accepted by the National Medical Products Administration.

Zhitong Finance APP News, Shanghai Jinmante Biotechnology Co., Ltd., a subsidiary of Stone Pharmaceutical Group (01093.HK), announced that its new drug application for the combined new adjuvant treatment of Anituzumab (KN026) developed in collaboration with Jiangsu Kanion Jereh Biopharmaceutical Co., Ltd. and the company's independently developed injectable docetaxel (albumin-bound) (HB1801) has been accepted by the National Medical Products Administration of the People's Republic of China (NMPA) and included in the priority review and approval process. The indication for this application is the combined treatment of Anituzumab with docetaxel (albumin-bound) carboplatin for early or locally advanced HER2-positive adult breast cancer.